Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “formulation”

865 pharma patents match "formulation" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 865
Index total 30,257
Page 24 / 37

Quick answer

This filtered view shows 865 pharmaceutical patents matching "formulation" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

865 results for “formulation” · 30,257 patents in full index Clear search

  1. US 9783515

    Radiomitigating pharmaceutical formulations

    The Regents of the University of California · Granted Oct 10, 2017 · Expires Oct 5, 2037

    granted
  2. US 9782416

    Pharmaceutical formulations of potassium ATP channel openers and uses thereof

    ESSENTIALIS, INC. · Granted Oct 10, 2017 · Expires Oct 5, 2037

    granted
  3. US 9775900

    Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof

    SANOCHEMIA PHARMAZEUTIKA AG · Granted Oct 3, 2017 · Expires Sep 28, 2037

    granted
  4. US 9770414

    Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

    Pacira Pharmaceuticals, Inc. · Granted Sep 26, 2017 · Expires Sep 21, 2037

    granted
  5. US 9770510

    Etanercept formulations stabilized with xylitol

    Coherus BioSciences, Inc. · Granted Sep 26, 2017 · Expires Sep 21, 2037

    granted
  6. US 9770507

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Sep 26, 2017 · Expires Sep 21, 2037

    granted
  7. US 9763883

    Abuse-deterrent drug formulations

    Collegium Pharmaceutical, Inc. · Granted Sep 19, 2017 · Expires Sep 14, 2037

    granted
  8. US 9757454

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Sep 12, 2017 · Expires Sep 7, 2037

    granted
  9. US 9758465

    Controlled release pharmaceutical formulations

    United Therapeutics Corporation · Granted Sep 12, 2017 · Expires Sep 7, 2037

    granted
  10. US 9757483

    Labeled iodinated tropane formulation

    Alseres Pharmaceuticals, Inc. · Granted Sep 12, 2017 · Expires Sep 7, 2037

    granted
  11. US 9757354

    Therapeutic formulations and methods

    Regents of the University of Minnesota · Granted Sep 12, 2017 · Expires Sep 7, 2037

    granted
  12. US 9744142

    Formulations of volatile anesthetics and methods of use for reducing inflammation

    The Board of Regents of the University of Texas System · Granted Aug 29, 2017 · Expires Aug 24, 2037

    granted
  13. US 9737530

    Process of making stable abuse-deterrent oral formulations

    Collegium Pharmaceutical, Inc. · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted
  14. US 9737600

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted
  15. US 9731009

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted
  16. US 9731008

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted
  17. US 9724345

    Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

    Platform Brightworks Two, Ltd. · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted
  18. US 9724367

    Injectable formulations for organ augmentation

    RegenMed (Cayman) LTD. · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted
  19. US 9724414

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted
  20. US 9724415

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted
  21. US 9713599

    Parenteral formulations of treprostinil

    United Therapeutics Corporation · Granted Jul 25, 2017 · Expires Jul 20, 2037

    granted
  22. US 9707284

    Formulations of peptides and chloroquines for the treatment of pathogenic immune responses in immune mediated diseases

    The Regents of the University of California · Granted Jul 18, 2017 · Expires Jul 13, 2037

    granted
  23. US 9707293

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jul 18, 2017 · Expires Jul 13, 2037

    granted
  24. US 9687448

    Nucleic acid lipid particle formulations

    Alnylam Pharmaceuticals, Inc. · Granted Jun 27, 2017 · Expires Jun 22, 2037

    granted